Apogee Therapeutics, Inc.
APGE
$39.94
$1.614.20%
| Weiss Ratings | APGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | APGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | APGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | APGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 27.08% | |||
| 30-Day Total Return | -6.02% | |||
| 60-Day Total Return | -10.25% | |||
| 90-Day Total Return | -23.25% | |||
| Year to Date Total Return | -15.29% | |||
| 1-Year Total Return | -38.73% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -46.58% | |||
| 52-Week Low % Change | 31.72% | |||
| Price | APGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $71.75 | |||
| 52-Week Low Price | $29.10 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Mar 22, 2024 | |||
| Valuation | APGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.23B | |||
| Enterprise Value | 1.51B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.28 | |||
| Earnings Per Share Growth | -56.00% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 3.10 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $39.94 | |||
| Enterprise Value/EBITDA (TTM) | -6.96 | |||
| Enterprise Value/EBIT | -6.95 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | APGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 57.25M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | APGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 394 5230 | |||
| Address | 221 Crescent Street Waltham, MA 02453 | |||
| Website | www.apogeetherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2022 | |||
| Profitability | APGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | APGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -23.46% | |||
| Return on Equity | -- | |||
| Income Statement | APGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -216.68M | |||
| EBIT (TTM) | -216.87M | |||
| Net Income (TTM) | -182.15M | |||
| Net Income Avl. to Common (TTM) | -182.15M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -111.81% | |||
| EPS Diluted (TTM) | -3.28 | |||
| EPS Diluted Growth (Q YOY) | -79.03% | |||
| Balance Sheet | APGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 520.65M | |||
| Cash Per Share (Q) | $9.09 | |||
| Total Current Assets (Q) | 529.71M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 716.79M | |||
| Current Ratio (Q) | 18.547 | |||
| Book Value Per Share (Q) | $12.35 | |||
| Total Assets (Q) | 753.95M | |||
| Total Current Liabilities (Q) | 28.56M | |||
| Total Debt (Q) | 11.83M | |||
| Total Liabilities (Q) | 37.16M | |||
| Total Common Equity (Q) | 716.79M | |||
| Cash Flow | APGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -300.46M | |||
| Cash from Financing (TTM) | 495.11M | |||
| Net Change in Cash (TTM) | 23.47M | |||
| Levered Free Cash Flow (TTM) | -113.42M | |||
| Cash from Operations (TTM) | -171.17M | |||
